Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06115967 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants | PHASE1 | COMPLETED | 40 | — | — | Nov 15, 2023 | Oct 16, 2025 | Dec 1, 2025 | 2 | Canada, United Kingdom |
To assess the safety and tolerability of AZD6912 in healthy participants.
| Arm | Type | Description |
|---|---|---|
| AZD6912 Dose 1 | EXPERIMENTAL | Participants will receive AZD6912 Dose 1. |
| AZD6912 Dose 2 | EXPERIMENTAL | Participants will receive AZD6912 Dose 2. |
| AZD6912 Dose 3 | EXPERIMENTAL | Participants will receive AZD6912 Dose 3. |
| AZD6912 Dose 4 | EXPERIMENTAL | Participants will receive AZD6912 Dose 4. |
| AZD6912 Dose 5 | EXPERIMENTAL | Participants will receive AZD6912 Dose 5. |
| AZD6912 Dose 6 | EXPERIMENTAL | Participants will receive AZD6912 Dose 6. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive Placebo. |
| AZD6912 additional Japanese cohort 1 | EXPERIMENTAL | Participants will receive AZD6912. |
| AZD6912 additional Japanese cohort 2 | EXPERIMENTAL | Participants will receive AZD6912. |
| Name | Type | Description |
|---|---|---|
| AZD6912 | DRUG | AZD6912 will be administered as a single sub-cutaneous dose. |
| Placebo | DRUG | Placebo will be administered as a single sub-cutaneous dose. |
Inclusion Criteria: * Females must have a negative pregnancy test. * Contraceptive use by males and females should be consistent with local regulations. * Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg. * For optional Japanese participants only: * Partici...